But rates alone don't tell the full story. ARKK was also structurally vulnerable in ways that weren't obvious during the bull market. The fund held concentrated positions in relatively illiquid stocks — meaning that when redemptions came and Wood had to sell, she was selling into markets where she was often the largest or one of the largest holders. Selling pressure from ARKK itself became a factor in the price declines of ARKK holdings, creating a feedback loop that accelerated losses.

Teladoc is the poster child for this dynamic. The telehealth company was a massive ARKK position — Wood was a consistent buyer as the stock declined from over $300 to eventually near single digits. Dollar-cost averaging into a fundamentally impaired business with public conviction is a strategy that looks courageous right up until it looks catastrophic. Teladoc never recovered.

The accountability question Wall Street never asks

Here's my pet peeve with financial media coverage of celebrity fund managers: we love them when they're right, and we move on when they're wrong. Nobody in mainstream financial media has done a serious accounting of how many retail investors bought ARKK at elevated prices because of the relentless media coverage in 2020 and 2021 — coverage that presented Wood's views as revealed truth rather than one fallible investment thesis among many.

If you told a friend in early 2021 that ARKK was risky and would underperform a basic S&P 500 index fund over the following five years, that friend might have laughed at you. The media ecosystem around Wood made skepticism feel like stupidity. The people who paid the price for that atmosphere weren't the journalists or the media companies. They were the regular investors who bought at $150 and are still waiting to get back to even.

Wood has been consistent in her conviction — she has maintained that her investment themes (AI, genomics, fintech disruption) will eventually play out, and she continues to manage the fund according to the same methodology. That intellectual consistency deserves acknowledgment. But conviction is not a substitute for returns, and ARKK's five-year performance record is what investors are actually left with.

What retail investors should take from this

The ARKK story is a near-perfect case study in the danger of buying a narrative instead of an investment. Wood's thesis was compelling. Her communication was excellent. The media coverage was overwhelming. None of that made the risk any lower.

Concentrated active funds that promise to beat the market through high-conviction thematic bets can work. They can also fail spectacularly. Before you put money into any fund with a celebrity manager attached, ask yourself: what does this person's five-year record actually look like, net of fees, compared to a basic index fund? If you can't answer that question in 30 seconds, the fund's marketing has already done its job on you.